Skip to content
LATEST
Health

WHO Terminates Hydroxychloroquine and Lopinavir/Ritonavir COVID-19 Treatment Trials

The WHO has discontinued hydroxychloroquine and lopinavir/ritonavir trials for hospitalized COVID-19 patients after interim results showed no significant…

WHO Terminates Hydroxychloroquine and Lopinavir/Ritonavir COVID-19 Treatment Trials

International clinical trials for hydroxychloroquine and lopinavir/ritonavir as treatments for hospitalized COVID-19 patients have been discontinued. Interim results indicate these interventions provide little to no reduction in mortality compared to standard care protocols. Investigators have ceased these specific trial arms with immediate effect.

While the interim data did not confirm increased mortality, clinical laboratory findings from associated sub-trials identified safety signals. These findings will be detailed in forthcoming peer-reviewed publications. The decision to halt these arms is limited to the treatment of hospitalized patients.

This termination does not preclude the evaluation of these drugs in non-hospitalized settings or as prophylactic measures. The findings necessitate a shift in clinical research focus toward alternative therapeutic candidates for severe COVID-19 cases. Future institutional resource allocation should account for the lack of efficacy demonstrated by these specific pharmaceutical interventions.

More stories

Latest news